Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players

globenewswire.com
GSK GlaxoSmithKline is mentioned as a leading participant in the global influenza vaccine market, which is projected to grow significantly. The article does not provide specific sentiment towards GSK's performance or prospects. PFE Pfizer is listed as a leading participant in the global influenza vaccine market. The article highlights the market's growth potential but does not offer specific sentiment or details about Pfizer's role or performance within it. SNY Sanofi is identified as a leading player in the global influenza vaccine market. The article forecasts market expansion but provides no specific sentiment or performance indicators for Sanofi. MRNA Moderna reported positive Phase 3 trial results for its mRNA-1083 vaccine candidate, showing a stronger immune response than comparators. This indicates strong potential for future growth and market success.

Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players Dublin, Aug. 07, 2026 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccine Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering.

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, expanding at a compound annual growth rate of approximately 7% between 2025 and 2030. Market growth is being supported by rising public health awareness, an expanding geriatric population, government immunization programs, recurring seasonal outbreaks and continued investment in vaccine research and development.

Influenza remains a significant global healthcare concern, causing an estimated three million to five million severe cases and 290,000 to 650,000 deaths annually. Older adults, young children, pregnant women and people with underlying health conditions face an elevated risk of hospitalization and severe outcomes. In the United States, approximately 85% of influenza-related deaths and 52% of associated hospitalizations occur among adults aged 65 and older.

Government agencies and international organizations, including the World Health Organization, continue to promote influenza vaccination through public awareness campaigns, reimbursement policies and free or subsidized immunization programs. These initiatives are improving vaccine accessibility and supporting sustained demand across developed and emerging healthcare markets.

Influenza Vaccine Market Segmentation

Regional Market Outlook

North America led the global influenza vaccine market in 2024. Regional growth is supported by strong healthcare infrastructure, insurance coverage, public education initiatives, government-sponsored vaccination programs and regulatory support. The United States remains North America’s largest market, benefiting from high healthcare expenditure and continued advances in vaccine production.

Asia Pacific is forecast to experience the fastest growth through 2030. Key factors include its large population, expanding healthcare infrastructure, government vaccination initiatives, rising insurance coverage and heightened awareness following previous influenza outbreaks and the COVID-19 pandemic. China holds the largest share of the regional market, supported by an aging population, domestic vaccine production, pharmaceutical research and development, and increasing adoption of artificial intelligence in healthcare.

Market Drivers, Challenges and Emerging Trends

Primary influenza vaccine market growth drivers include the increasing disease burden among older adults, rapid urbanization, seasonal epidemics, favorable government policies and greater investment in pandemic preparedness. Continued expansion of public and private vaccination services is also improving access in underserved markets.

Market participants nevertheless face complex clinical development and regulatory requirements, regional differences in product approvals, high development costs and unequal vaccine access. Manufacturing and distribution timelines can also create challenges when producers must respond quickly to changing seasonal strain recommendations.

Artificial intelligence and machine learning are emerging as influential market trends. These technologies can support strain selection, antigen design, clinical data analysis, outbreak monitoring and supply chain planning. Advances in vaccine administration, cell-based production and mRNA platforms are also expected to improve development efficiency and strengthen future market growth.

Competitive Landscape and Recent Developments

The global influenza vaccine market remains fragmented, with established pharmaceutical companies and specialist vaccine manufacturers investing in advanced technologies, production capacity and emerging markets. Leading participants include:

Recent activity demonstrates continued innovation and geographic expansion. In June 2024, Sinovac announced a US$100 million investment in Brazil to establish local production of vaccines and monoclonal antibodies while advancing cell therapy initiatives. Moderna also reported that its Phase 3 trial of mRNA-1083, a combination influenza and COVID-19 vaccine candidate, met its primary endpoints and generated a stronger immune response than licensed comparators.

With governments prioritizing immunization, manufacturers advancing production technologies and healthcare systems broadening vaccine access, the global influenza vaccine market is positioned for sustained expansion through 2030.

For more information about this report visit https://www.researchandmarkets.com/r/6woerm

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.